BrainStorm Cell Therapeutics: Funding, Investors & Team (Oct 2026)
BrainStorm Cell Therapeutics is a biotechnology company that is focused on developing advanced stem cell therapies for serious neurodegenerative illnesses like ALS, MS, and PD. Their unique technology, called NurOwn™, allows for the growth and differentiation of a patient's own stem cells into cells that secrete neurotrophic factors. These cells can then be transplanted near the damaged area in the hope of treating and potentially curing these diseases. Currently, BrainStorm is conducting a Phase IIa ALS clinical trial at the Hadassah University Medical Center in Jerusalem, where 12 patients will receive neuron cell transplants in increasing doses. The company also has plans to begin a Phase II trial in the US pending FDA approval. In February 2011, NurOwn received Orphan Drug designation from the FDA, and the scientific team has published more than 20 studies in prestigious scientific journals on the mechanism of action, pharmacology, and efficacy of neuron cells.
BrainStorm Cell Therapeutics has raised $12.9M across 4 funding rounds on record, the most recent an undisclosed round of $400k announced in May 2026.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BrainStorm Cell Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
BrainStorm Cell Therapeutics Funding Rounds
BrainStorm Cell Therapeutics raised $7.5M in an undisclosed round announced in Jul 2023.
11 months later, an undisclosed round of $4.0M was announced in Jun 2024.
1.7 years later, an undisclosed round of $1.0M was announced in Feb 2026.
3 months later, an undisclosed round of $400k was announced in May 2026.
BrainStorm Cell Therapeutics Founders and Leadership Team
Contact details for the BrainStorm Cell Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →BrainStorm Cell Therapeutics Funding Compared to Other Biotechnology Startups
BrainStorm Cell Therapeutics' latest round of $400k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BrainStorm Cell Therapeutics in Biotechnology and New York
Companies Similar to BrainStorm Cell Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
BrainStorm Cell Therapeutics Funding FAQs
What does BrainStorm Cell Therapeutics do?
BrainStorm Cell Therapeutics is a biotechnology company that is focused on developing advanced stem cell therapies for serious neurodegenerative illnesses like ALS, MS, and PD. Their unique technology, called NurOwn™, allows for the growth and differentiation of a patient's own stem cells into cells that secrete neurotrophic factors. These cells can then be transplanted near the damaged area in the hope of treating and potentially curing these diseases. Currently, BrainStorm is conducting a Phase IIa ALS clinical trial at the Hadassah University Medical Center in Jerusalem, where 12 patients will receive neuron cell transplants in increasing doses. The company also has plans to begin a Phase II trial in the US pending FDA approval. In February 2011, NurOwn received Orphan Drug designation from the FDA, and the scientific team has published more than 20 studies in prestigious scientific journals on the mechanism of action, pharmacology, and efficacy of neuron cells.
How much funding has BrainStorm Cell Therapeutics raised?
BrainStorm Cell Therapeutics has raised $12.9M across 4 rounds on record. The most recent is an undisclosed round of $400k announced in May 2026.
When did BrainStorm Cell Therapeutics last raise funding?
BrainStorm Cell Therapeutics' most recent funding round on record is an undisclosed round of $400k, announced in May 2026.
Who founded BrainStorm Cell Therapeutics?
FundedIQ lists Chaim Lebovits (Founder), Daniel Offen (Founder) at BrainStorm Cell Therapeutics.
Where is BrainStorm Cell Therapeutics headquartered?
BrainStorm Cell Therapeutics is based in New York, United States.
How many employees does BrainStorm Cell Therapeutics have?
BrainStorm Cell Therapeutics is in the 11-50 employee band.
How does BrainStorm Cell Therapeutics' funding compare to other Biotechnology startups?
BrainStorm Cell Therapeutics' latest round of $400k is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BrainStorm Cell Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BrainStorm Cell Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.